bullish

Grifols

Grifols S A (GRFS) - Wednesday, Mar 13, 2024

194 Views12 Jun 2024 18:46
Syndicated
SUMMARY
  • Grifols facing controversy over high debt, aggressive accounting practices, and financial sustainability doubts
  • Despite challenges, Grifols is a major player in blood plasma-derived therapies market and has improved margins
  • Company generated over EUR700m in free cash flow in 2020, expected to return to positive cash flow in 2025 with decreased costs and slowed growth investments; recent asset sale to reduce debt and new CEO joining to work towards stable financial future

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Value Investors Club
External reports (aggregated public sources)
Value Investors Club
Equity Bottom-UpEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Grifols S A (GRFS) - Wednesday, Mar 13, 2024
    12 Jun 2024
x